City-based drug maker Natco Pharma today said it has entered into an exclusive agreement with Mabxience,the bio-similar division of Swiss-based Chemo Sa Lugano.
Under the agreement,Natco will purchase four Monoclonal antibodies or mAb drug substances from Chemo and use the same for manufacturing finished dosage pharmaceutical formulations.
Chemo Sa Lugano is an integrated healthcare multinational involved into different fields of pharmaceutical business,including bio-similars and branded pharmaceuticals.
Three of these products -Trastuzumab,Bevacizumab,Rituximab belong to the oncology segment,while Etanercept is for auto-immune disease,Natco said in a statement.
Natco’s obligations under the agreement will include manufacturing of drug products,undertaking local clinical trials,filing registration of dossiers,applying for market authorisations and commercialising the product in India and a few other Asian countries,it said.
Oncology is the largest therapy area within the mAb market,with eight marketed products. The mAb market is highly innovative and a key trend has been the move from murine to humanised and fully human antibodies,with insignificant generic presence.
The market for mAbs has grown rapidly worldwide and is pegged at around USD 35 Billion. With the product combinations chosen by Natco,the mAb initiative is likely to be completed in a period of 24 to 36 months.